- Home
- EQR vs WAT Comparison
EQR vs WAT Comparison
Compare EQR & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQR
- WAT
- Stock Information
- Founded
- EQR 1993
- WAT 1958
- Country
- EQR United States
- WAT United States
- Employees
- EQR N/A
- WAT N/A
- Industry
- EQR Real Estate Investment Trusts
- WAT Biotechnology: Laboratory Analytical Instruments
- Sector
- EQR Real Estate
- WAT Industrials
- Exchange
- EQR Nasdaq
- WAT Nasdaq
- Market Cap
- EQR 27.9B
- WAT 22.5B
- IPO Year
- EQR 1993
- WAT 1995
- Fundamental
- Price
- EQR $73.38
- WAT $381.33
- Analyst Decision
- EQR Buy
- WAT Hold
- Analyst Count
- EQR 19
- WAT 13
- Target Price
- EQR $75.22
- WAT $363.92
- AVG Volume (30 Days)
- EQR 1.4M
- WAT 528.9K
- Earning Date
- EQR 01-28-2025
- WAT 11-01-2024
- Dividend Yield
- EQR 3.67%
- WAT N/A
- EPS Growth
- EQR 35.67
- WAT N/A
- EPS
- EQR 2.44
- WAT 10.48
- Revenue
- EQR $2,940,829,000.00
- WAT $2,905,147,000.00
- Revenue This Year
- EQR N/A
- WAT $0.53
- Revenue Next Year
- EQR $4.01
- WAT $5.59
- P/E Ratio
- EQR $30.15
- WAT $37.36
- Revenue Growth
- EQR 3.33
- WAT N/A
- 52 Week Low
- EQR $57.33
- WAT $279.24
- 52 Week High
- EQR $78.83
- WAT $395.50
- Technical
- Relative Strength Index (RSI)
- EQR 44.80
- WAT 55.78
- Support Level
- EQR $73.38
- WAT $380.14
- Resistance Level
- EQR $78.32
- WAT $395.39
- Average True Range (ATR)
- EQR 1.14
- WAT 11.32
- MACD
- EQR -0.17
- WAT 0.57
- Stochastic Oscillator
- EQR 14.68
- WAT 74.26
About EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 299 apartment communities with around 80,000 units and is developing three additional properties with 977 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions.